

## Inflammation in children with chronic kidney disease linked to gut dysbiosis and metabolite imbalance

Johannes Holle<sup>1,2,3,\*</sup>, Hendrik Bartolomaeus<sup>2,3,4,5</sup>, Ulrike Löber<sup>2,3,4,6</sup>, Felix Behrens<sup>1,3,6,7</sup>, Theda U. P. Bartolomaeus<sup>2,3,4,6</sup>, Harithaa Anandakumar<sup>2,4,5</sup>, Moritz I. Wimmer<sup>2,3,4,5,8</sup>, Dai Long Vu<sup>4,9</sup>, Mathias Kuhring<sup>4,6,10</sup>, Andras Maifeld<sup>2</sup>, Sabrina Geisberger<sup>4,11</sup>, Stefan Kempa<sup>4,11</sup>, Philip Bufler<sup>1</sup>, Uwe Querfeld<sup>1</sup>, Stefanie Kitschke<sup>1</sup>, Denise Engler<sup>1</sup>, Leonard D. Kuhrt<sup>1,4</sup>, Oliver Drechsel<sup>12</sup>, Kai-Uwe Eckardt<sup>5</sup>, Sofia K. Forslund<sup>2,3,4,6,13</sup>, Andrea Thürmer<sup>14</sup>, Victoria McParland<sup>2,4</sup>, Jennifer A. Kirwan<sup>4,9</sup>, Nicola Wilck<sup>2,3,5,6,#,\*</sup>, Dominik Müller<sup>1,#,\*</sup>

- 1 1 Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité -
- 2 Universitätsmedizin Berlin, 13353 Berlin, Germany
  
- 3 2 Experimental and Clinical Research Center (ECRC), a cooperation of Charité -
- 4 Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine (MDC), 13125
- 5 Berlin, Germany
  
- 6 3 DZHK (German Centre for Cardiovascular Research), partner site Berlin, 13316 Berlin,
- 7 Germany.
  
- 8 4 Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125
- 9 Berlin, Germany
  
- 10 5 Department of Nephrology and Medical Intensive Care Medicine, Charité -
- 11 Universitätsmedizin Berlin, 13353 Berlin, Germany
  
- 12 6 Charité - Universitätsmedizin Berlin and Berlin Institute of Health, 10117 Berlin, Germany
  
- 13 7 Institute of Physiology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany
  
- 14 8 Department of Internal Medicine IV, Division of Endocrinology, Diabetology and
- 15 Nephrology, University Hospital of Tübingen, 72076 Tübingen, Germany
  
- 16 9 Berlin Institute of Health Metabolomics Platform, Berlin Institute of Health (BIH), 10178
- 17 Berlin, Germany
  
- 18 10 Core Unit Bioinformatics, Berlin Institute of Health (BIH), 10178 Berlin, Germany
  
- 19 11 The Berlin Institute for Medical Systems Biology, 10115 Berlin, Germany

20 12 MF1 Bioinformatics, Robert Koch Institute, 13353 Berlin, Germany

21 13 European Molecular Biology Laboratory, 69117 Heidelberg, Germany

14 MF2 Genome Sequencing, Robert Koch Institute, 13353 Berlin, Germany

22

23 # Authors contributed equally to this publication

24 \* corresponding authors

## 25 **Abstract**

26 Chronic kidney disease (CKD) is characterized by a sustained pro-inflammatory response.  
27 The underlying mechanisms are incompletely understood, but may be linked to gut dysbiosis.  
28 Dysbiosis has been described in adults with CKD; however, comorbidities limit CKD-specific  
29 conclusions. We analyzed the fecal microbiome, metabolites and immune phenotypes in  
30 children at three different CKD stages (G3-G4, G5 (hemodialysis), after kidney  
31 transplantation) and healthy controls. Serum TNF- $\alpha$  and sCD14 were stage-dependently  
32 elevated, indicating inflammation and gut barrier dysfunction. We observed microbiome  
33 alterations in CKD, including a diminished production of short-chain fatty acids. Bacterial  
34 tryptophan metabolites were increased in CKD. CKD serum activated the aryl hydrocarbon  
35 receptor and stimulated TNF- $\alpha$  production by monocytes, corresponding to a shift towards  
36 intermediate/non-classical monocytes. Unsupervised T cell analysis revealed pro-  
37 inflammatory shifts in MAIT and Treg cells. Thus, gut barrier dysfunction and microbial  
38 metabolites exacerbate inflammation and may therefore contribute to the increased  
39 cardiovascular burden in CKD.

## 40 **Introduction**

41 Despite ongoing efforts to improve the treatment of patients with chronic kidney disease  
42 (CKD), they still suffer from high morbidity and mortality, primarily due to cardiovascular  
43 diseases (CVD)<sup>1</sup>. Besides known risk factors such as arterial hypertension and proteinuria<sup>1</sup>,  
44 recent studies suggest a crucial role for microbially produced metabolites in promoting  
45 inflammation<sup>2,3</sup> and, as a consequence, progression of CKD and CVD<sup>1,3,4</sup>.

46 There is longstanding evidence showing that an imbalance in the bacterial community  
47 residing in the gut with changes in its functional composition, termed dysbiosis, is common in  
48 adult patients with CKD<sup>5,6</sup>. Beyond the influence of CKD, a variety of other factors, such  
49 influence of diet and drugs, are suspected to contribute to dysbiosis in CKD<sup>6</sup>. These changes  
50 are paralleled by an altered bacterial metabolism of nutrients and a systemic accumulation of  
51 uremic toxins of bacterial origin, such as indoxyl sulfate (IxS)<sup>7</sup>. It is conceivable that dysbiosis  
52 and metabolite dysbalance aggravate systemic inflammation, which could provide a potential  
53 mechanism for the high rate of premature cardiovascular events<sup>3</sup>.

54 Recently, we demonstrated a positive association between IxS and early cardiovascular  
55 disease in children with CKD<sup>8</sup>. In contrast to adults with CKD, children are less affected by  
56 risk factors such as diabetes, obesity, and metabolic syndrome, but mainly suffer from  
57 congenital anomalies of the kidney and urinary tract (CAKUT)<sup>9</sup>. Thus, a pediatric cohort  
58 offers the unique opportunity to analyze the impact of CKD on microbiota-host interaction  
59 more specifically.

60 Our cohort includes pediatric CKD patients, those on hemodialysis (HD), patients after  
61 kidney transplantation (KT) and age-matched healthy controls (HC). We show, for the first  
62 time a CKD specific dataset of gut microbiome composition, altered microbial metabolism of  
63 nutrients, and the corresponding impact on inflammation and immune cell dysregulation in  
64 children suffering from CKD. We connect the bacterial metabolite dysbalance to a pro-  
65 inflammatory immune cell signature, emphasizing the importance of the microbiota for  
66 chronic inflammation in CKD. The fact that these dysbiosis-driven immunological changes

67 are already detectable in children with CKD highlights the potential of microbiota-targeted  
68 therapies to improve prognosis of CKD patients across all ages.

## 69 **Patients and methods**

### 70 **Study population**

71 In this cross-sectional study, we recruited patients from the Department of Pediatric  
72 Gastroenterology, Nephrology, and Metabolic Diseases at Charité University hospital in  
73 Berlin, Germany, between February 2018 and June 2018. Written informed consent was  
74 obtained from all participants and/or their parents prior to study entry. The study was  
75 approved by the local Ethical Review Board (EA2/162/17). All procedures performed were in  
76 accordance with the ethical standards of the institutional and national research committees  
77 and the 1964 Helsinki declaration and its later amendments or comparable standards.

78 Patients (age 3-18 years) were enrolled in the following groups:

- 79 - CKD group: CKD stage G3-G4, estimated GFR (eGFR)  $15-60 \text{ ml/min} \cdot 1.73\text{m}^2$
- 80 - HD group: CKD stage G5D, patients on maintenance hemodialysis, enrolled earliest  
81 four weeks after initiation of HD
- 82 - KT group: patients after successful KT, earliest four weeks after KT, without a  
83 history of rejection or chronic graft failure,  $\text{eGFR} > 60\text{ml/min} \cdot 1.73\text{m}^2$
- 84 - HC group: normal kidney function, treated at the hospital for reasons other than  
85 kidney disease

86 We excluded patients with a body weight below 15kg, acute or chronic inflammatory  
87 diseases, fever, diabetes, chronic liver disease, inflammatory bowel disease, or other  
88 gastrointestinal disorders (constipation, diarrhea, short bowel syndrome). Patients with  
89 antibiotic prophylaxis or treatment within the four weeks prior to recruitment were excluded.

### 90 **Statistical analysis**

91 Microbiome and metabolome analysis: Alpha diversities of microbial communities (Shannon  
92 diversity as computed by RTK, defined at the OTU level) were compared between groups  
93 using Kruskal-Wallis (KW) test. Beta diversity was assessed using Euclidean (metabolome)

94 and Canberra (microbiome) dissimilarity index between samples computed using vegan  
95 package v2.5-7. Principal Coordinates Analysis (PCoA) was performed using the vegan  
96 package v2.5-7 (employing Euclidean and Canberra distance metrics as above).  
97 PERMANOVA was performed using the adonis function from the vegan package v2.5-7. We  
98 estimate differential abundance on phylum and genus level between groups using the  
99 package DESeq2 v1.30.1. The DESeq2 pipeline uses negative binomial distribution models  
100 to test for differential abundance between testing conditions. We ran the pipeline with  
101 normalized counts under default settings. *P* values were adjusted according to Benjamini-  
102 Hochberg (BH) false discovery rates (FDR) correction. A q-value of <0.1 was considered  
103 statistical significant.

104 For each pair of patient groups, features from the TRP analysis were compared using two-  
105 sided Mann-Whitney-U (MWU) tests with effect sizes calculated as Cliff's delta metric per the  
106 R ordom package v3.1. Effect sizes were taken as Spearman's rho. All significance  
107 estimates were adjusted for multiple tests using BH-FDR correction. To assess the effect of  
108 patient groups on tryptophan pathway metabolites (concentrations), multifactor ANOVAs  
109 were calculated per metabolite to account for multiple groups as well as potential  
110 confounders (including age, sex, ethnical background, underlying disease category, BMI, and  
111 eGFR).

112 The co-abundance network of host, microbiome and metabolome features was calculated  
113 from the dataset as a whole by assessing pairwise Spearman correlations and adjusted for  
114 multiple testing using BH-FDR correction as implemented in the R psych package v1.9.12.  
115 Edges for which absolute rho > 0.3 and Q < 0.1 were visualized using the iGraph R package.  
116 Correlations were separately also assessed stratifying for group effects using the R coin  
117 package v1.3.1.

118 Flow cytometry: For all FlowSOM clusters we computed log<sub>2</sub> fold changes (fc). Cluster log<sub>2</sub>fc  
119 were visualized using ggplot2 package v3.3.5. For all subpopulations of Treg and MAIT cells,  
120 we calculated log<sub>2</sub>fc and assessed statistical significance using two-sided MWU-tests

121 between HD and HC with BH-FDR correction. A q-value of  $<0.1$  was considered statistically  
122 significant. Data was visualized using the EnhancedVolcano package v4.1.2.

123 Boxplots: Analysis and graphical representation was performed in GraphPad Prism 9.3.1  
124 (GraphPad Software, CA, USA). Boxplots depict median and interquartile range with  
125 whiskers from min to max. Overlaid data points represent individual patients or  
126 measurements. Normality was assessed using Q-Q-plots and Shapiro-Wilk test. For more  
127 than two groups we performed one-way ANOVA with Tukey post-hoc test or KW test with  
128 Dunn's post-hoc test, as appropriate. For two group comparisons, we performed two-sided  
129 Student's t-test or two-sided MWU test, as appropriate.

130 For all analysis *P* value of  $<0.05$  (unadjusted or adjusted, as appropriate) and a *Q* value of  
131  $<0.1$  was considered statistically significant.

## 132 **Results**

### 133 **Childhood CKD marked by arterial hypertension, inflammation and leaky gut**

134 Ten healthy individuals (HC) and 38 patients were enrolled in the study (Supplementary  
135 Figure 1). Baseline characteristics are given in Table 1. Participant mean age was  $10.6 \pm 3.8$   
136 years with 21 females and 27 males. CAKUT was the most prevalent underlying disease  
137 category. Patients treated with HD had a median time on dialysis of six months (range 3 – 29  
138 months) with a median residual diuresis of 50 ml per day (range 0 – 1800 ml per day) and a  
139 mean Kt/Vof  $1.56 \pm 0.27$  (SD), indicating adequacy of HD treatment. Patients after KT had a  
140 stable graft function with a mean eGFR of  $78.8 \pm 19.4$  ml/min\*1.73m<sup>2</sup>. The median time from  
141 transplantation was 48 months (range 10 – 125 months).

142 Both the CKD group (CKD stage G3-G4) and the HD group (CKD stage G5D) were  
143 hypertensive (83% and 91%, respectively) and received antihypertensive treatment ( $1.8 \pm$   
144  $1.5$  antihypertensive drugs in the CKD group and  $2.4 \pm 1.9$  drugs in the HD group, Figure 1a,  
145 Table 1). Six HD patients (55%) exhibited hypertensive blood pressures at the time of study  
146 enrolment despite treatment (Table 1). In the HD and CKD groups serum levels of the pro-  
147 inflammatory cytokine TNF- $\alpha$  were stage-dependently increased and significantly higher than  
148 in the HC group (Figure 1b), while differences in the levels of other pro- and anti-  
149 inflammatory cytokines did not reach significance (Supplementary Table 2). Notably, TNF- $\alpha$   
150 was also significantly elevated in patients after KT compared to HC (Figure 1b). We next  
151 investigated serum levels of the tight junction protein zonulin-1 (Zo-1) and the  
152 lipopolysaccharide (LPS) binding protein soluble CD14 (sCD14), which were elevated in  
153 CKD and HD compared to control and KT (Figure 1c), indicating stage-dependent intestinal  
154 barrier dysfunction and CKD-associated endotoxemia. Thus, in the absence of classical  
155 cardiovascular risk factors other than hypertension, CKD in children is characterized by  
156 elevated serum markers of inflammation and leaky gut.

### 157 **Microbiome alterations in CKD**



158 Since intestinal barrier dysfunction may be associated with dysbiosis, we next sought to  
159 analyze the taxonomic composition of the gut microbiome. We performed 16S amplicon  
160 sequencing in n=32 study participants with available fecal samples. We observed a high  
161 interindividual compositional variability at phylum level (Figure 2a). Microbiome richness and  
162 diversity, as measured by the Shannon diversity index, tended to be lower in CKD and HD  
163 patients compared to HC but this difference did not reach statistical significance (Figure 2b).  
164 However, analysis of beta diversity (Canberra distance) indicated significant differences in  
165 microbiome composition between groups, with CKD and HD groups separating most clearly  
166 from the HC (Figure 2c,  $p = 0.01$ ). Analysis of bacterial composition on genus level revealed  
167 significant alterations predominantly in HD patients (Figure 2d). First, relative abundances of  
168 Firmicutes and Actinobacteria such as *Fusicatenibacter* (belonging to the family of  
169 Lachnospiraceae), *Subdoligranulum* (Ruminococcaceae), and *Bifidobacterium*  
170 (*Bifidobacteriaceae*) were significantly diminished in HD patients compared to HC. Second,  
171 we found an increase in relative abundance of Proteobacteria and Bacteroidetes, such as  
172 *Citrobacter* (*Enterobacteriaceae*), *Parasutterella* (*Parasutterellaceae*), and several genera of  
173 *Bacteroides* (*Bacteroidaceae*) in CKD and HD groups compared to HC and KT. Taken  
174 together, the taxonomic microbiome changes in CKD are stage-dependent, most pronounced  
175 in the HD group and less pronounced after KT. The abundance of proteolytic bacteria (such  
176 as *Citrobacter*) increases in CKD whereas saccharolytic bacteria (such as *Bifidobacterium*)  
177 decrease.

### 178 **CKD stage-dependent dysbalance of bacterial metabolites**

179 To investigate the functional effects of the observed alterations in microbiome composition  
180 on host physiology, we focused a plasma metabolite analysis on tryptophan (TRP)  
181 metabolites and SCFA. Dietary TRP is a substrate for both cellular metabolism and bacterial  
182 proteolytic fermentation and the latter is a source of microbial produced uremic toxins, such  
183 as IxS. We found significant differences in the abundance of TRP metabolites in CKD and  
184 HD compared to the HC and KT groups (Figure 3a). CKD and HD patients showed a large-

185 scale shift from TRP to its indole and kynurenine (KYN) metabolites, which was  
186 predominantly driven by an increase of IxS (Figure 3b). We found a significant decrease in  
187 plasma TRP concentrations in patients with CKD and HD, while IxS and 5 KYN metabolites  
188 (KYN, kynurenic acid (KA), 3-OH-kynurenine (3OH-KYN), anthranilic acid (AA), xanthurenic  
189 acid (XA)) were significantly elevated (Figure 3c). Interestingly, patients after KT had similar  
190 metabolite levels compared to HC with the exception of KYN and 3OH-KYN (Figure 3c).  
191 Individual values of TRP, IxS and, KA are shown across the different groups in Figure 3d-f.  
192 The activation of the cellular KYN pathway is also indicated by the ratio of KYN to TRP,  
193 which was significantly elevated in CKD and HD (Figure 3g). A multivariate ANOVA showed  
194 that age, sex, ethnic background, underlying disease category, and BMI did not confound  
195 metabolite levels. Only group and eGFR had an impact on several of the compounds  
196 (Supplementary Table 3), confirming their accumulation with declining eGFR. Because indole  
197 and KYN metabolites have been shown to activate the aryl hydrocarbon receptor (AhR), a  
198 transcription factor and potential mediator of microbiome-host interactions, we measured the  
199 AhR activating potential of serum from the HD and HC group *in vitro* using a cell-based  
200 reporter assay. Serum from HD patients induced a significantly higher AhR activity as  
201 compared to HC (Figure 3h). Similarly, IxS activates the AhR in a dose-dependent manner  
202 (Supplementary Figure 2).

203 To further functionally validate our findings of decreased abundancies of saccharolytic  
204 microbes, we measured the abundance of a central enzyme for bacterial SCFA production  
205 by qPCR of fecal DNA using degenerate primers. The abundancy of the butyrate gene was  
206 lower in the DNA extracted from fecal samples of HD patients relative to the other patient  
207 groups (Supplementary Figure 3a). Next, we measured SCFA in serum. The SCFA  
208 propionate and isobutyrate were reduced in patients with HD compared to HC, while serum  
209 concentrations of butyrate did not differ significantly between groups (Supplementary Figure  
210 3b). Thus, we were able to show on a functional level that the observed stage-dependent  
211 microbiome changes have an impact on the production and abundance of bacterial  
212 metabolites.

213 In order to comprehensively visualize the relationship of clinical, microbial and metabolomic  
214 parameters, we performed a correlation network analysis (Figure 4). Here, TNF- $\alpha$  correlated  
215 positively with sCD14, Proteobacteria, IxS, several KYN metabolites and biomarkers of  
216 kidney function (Figure 4a, positive correlations). Conversely, the SCFA propionate and  
217 isobutyrate correlated inversely with TNF- $\alpha$ , IxS, KYN metabolites and kidney function  
218 (Figure 4b, negative correlations). Firmicutes correlated positively with microbial diversity,  
219 butyrate and I3PA. These associations support our assumption of kidney function as a  
220 catalyst of gut bacteria-driven inflammation.

### 221 **Monocyte subsets contribute to the pro-inflammatory phenotype in CKD**

222 The AhR is expressed in various immune cells including myeloid cells and is known to  
223 modulate their function<sup>10</sup>. It is assumed that the accumulation of AhR ligands in CKD leads to  
224 immune cell activation. We therefore isolated monocytes from healthy donors and incubated  
225 them with serum from HD patients or HC. Monocytes incubated with HD serum showed a  
226 significantly higher TNF- $\alpha$  production (Figure 5a). Similarly, incubation of isolated monocytes  
227 with IxS dose-dependently increased TNF- $\alpha$  production which could be reversed by co-  
228 incubation with the synthetic AhR-antagonist CH-223191, highlighting the importance of  
229 AhR-mediated immune activation in CKD (Figure 5a).

230 In order to get a broader overview of changes in relevant immune cell populations in CKD,  
231 we re-collected peripheral blood mononuclear cells (PBMC) from seven HC and six HD  
232 patients for immunophenotyping using flow cytometry. Unsupervised FlowSOM analysis<sup>11</sup> of  
233 our monocyte and dendritic cell targeting flow panel (see Supplementary table 1,  
234 supplementary figure 4, Figure 5b), showed phenotypic alterations of monocytes (cluster 3,  
235 Figure 5c) being decreased (Figure 5d) and dendritic cell (cluster 7, Figure 5c) being  
236 increased (Figure 5d) in HD patients. Using classical hierarchical gating, we observed similar  
237 abundances of total monocytes (identified by HLA-DR, CD14, and CD16 as described in<sup>12</sup>),  
238 but a significant shift from classical (CD14+CD16-) towards non-classical (CD14-CD16+) and  
239 intermediate (CD14+CD16+) monocytes in HD (Figure 5e), the latter two being known for

240 their potent production of TNF- $\alpha$ <sup>13</sup>. Hierarchical gating within the dendritic cell population  
241 revealed no significant differences of dendritic cell types (Supplementary Figure 5). Thus, HD  
242 patients are characterized by alterations within myeloid cells, showing a shift from classical to  
243 pro-inflammatory intermediate and non-classical monocytes.

#### 244 **Pro-inflammatory T cell subsets in CKD**

245 Since SCFA and TRP metabolites are known to modulate T cell differentiation and function,  
246 we expanded our flow cytometry to include analysis of T cells (Supplementary table 1, T  
247 surface panel, supplementary figure 4). We again performed FlowSOM analysis using 8  
248 clusters (Figure 6a). Mucosal associated invariant T (MAIT) cells and a subpopulation of  
249 regulatory T cells (Treg) (Clusters 6 and 3, respectively, Figure 6b) exhibited the largest  
250 effects between HD and HC patients (Figure 6c). We confirmed this finding by classical  
251 hierarchical gating, with circulating MAIT cells (CD3+CD161+TCRV $\alpha$ 7.2+) being decreased  
252 in HD (Supplementary Figure 6a). Next, we performed a more detailed analysis of MAIT cell  
253 subpopulations. After adjusting for multiple testing, we found a decrease of CD4-CD8- MAIT  
254 cells, while CD4+CD8- and CD4+CD8+ cells were enriched in HD (Figure 6d, f). Moreover,  
255 MAIT cells of HD patients displayed an effector memory phenotype (CD45RA-, CD62L-) and  
256 expressed more PD-1, indicative of increased activation. Importantly, upon *in vitro*  
257 restimulation, MAIT cells of HD patients secreted significantly more interleukin-17A (IL-17A)  
258 (Figure 6d, f).

259 In addition, we identified changes within a CD4+CD25+CD127- cell cluster (Cluster 3, Figure  
260 6a-c), indicating alterations in Treg subpopulations. Total Treg proportions were not altered  
261 between HC and HD (Supplementary Figure 6b). However, since different subpopulations  
262 with partly different functions are known to exist within the total Treg population, we extended  
263 the Treg characterization (Supplementary table 1, T surface and T activation)<sup>14</sup>. Adjusted for  
264 multiple testing, several Treg subpopulations, characterized by activation markers and  
265 chemokine receptors, were significantly changed in HD patients (Figure 6e). In detail, Treg  
266 from HD patients with a central-memory phenotype (CD45RA-, CD62L+) showed a higher

267 expression of PD-1 indicating activation state. Based on the expression of chemokine  
268 receptors, Th1-like (CXCR3+), Th17-like (CXCR3-CCR6+CCR4+CCR10-) and Th22-like  
269 (CXCR3-CCR6+CCR4+CCR10+) Treg were significantly diminished in HD patients  
270 compared to HC (Figure 6e, g). Taken together, we observed significant alterations in T cell  
271 subtypes, namely MAIT cells and Treg, which play an important role in mucosal immunity  
272 and inflammation.

## 273 **Discussion**

274 Inflammation is a hallmark of CKD, detectable even at young age and particularly prognosis-  
275 determining. We show in children with CKD, that intestinal barrier dysfunction and dysbiosis  
276 are associated with a systemic bacterial metabolite imbalance that contributes to the pro-  
277 inflammatory phenotype of several immune cells including monocytes and T cells. We also  
278 provide novel insight into the microbiota-immune crosstalk mediated by TRP metabolites and  
279 SCFA in CKD. Thus, we demonstrate a stage-dependent aberration of the microbiome-  
280 immune axis, which is both a contributor to inflammation and a potential target for anti-  
281 inflammatory therapeutic strategies.

282 The young cohort enrolled for this study exhibits a markedly increased risk for cardiovascular  
283 disease, indicated by a high prevalence of arterial hypertension despite antihypertensive  
284 treatment as well as clear evidence of systemic inflammation (TNF- $\alpha$ ). Inflammation is  
285 considered to be a main driver of cardiovascular disease in CKD<sup>15</sup>. Early cardiovascular  
286 pathologies and complications in children with CKD have been described previously<sup>16,17</sup>, the  
287 burden of which accumulates with age and causes a fatal increase of CKD-associated  
288 mortality<sup>1</sup>. This is remarkable given that CKD occurs in children in the virtual absence of  
289 diseases that can cause both CKD and CVD, such as diabetes and metabolic syndrome.  
290 This is particularly relevant for the present study, as traditional comorbidities in adults  
291 represent additional influences on microbiota-immune interaction. Therefore, it can be  
292 assumed that the microbiome and immune signatures presented here are influenced to a  
293 smaller degree by traditional comorbidities and represent specific signatures of CKD.

294 For the first time, we demonstrate that children with CKD already exhibit considerable stage-  
295 dependent intestinal barrier dysfunction indicated by increased serum levels of Zo-1 and  
296 sCD14. Zo-1 regulates intestinal permeability<sup>18</sup> and has been associated with impaired  
297 barrier function in various conditions such as obesity, diabetes<sup>19</sup> and autoimmune diseases<sup>20</sup>.  
298 Impaired barrier function permits the translocation of luminal LPS into the circulation.  
299 Consequently, we detected a CKD stage dependent increase in serum levels of the LPS

300 binding protein sCD14, suggesting LPS-induced inflammation<sup>21-23</sup>. Elevated serum levels of  
301 sCD14 have been associated with an increased risk of CVD in two independent cohort  
302 studies<sup>24,25</sup>. Intestinal barrier dysfunction develops along with or as a consequence of  
303 dysbiosis, presumably as a consequence of a dysbalance of microbial metabolites, such as  
304 SCFA<sup>26,27</sup>. Therefore, we analyzed the composition of the gut microbiome in our cohort. In  
305 line with studies of adult CKD patients<sup>5,7,28,29</sup>, we observed CKD stage-dependent  
306 compositional changes. This microbial signature was most dominantly present in patients  
307 with HD displaying an increase of proteolytic bacteria such as *Citrobacter*  
308 (*Enterobacteriaceae*) and a decrease of saccharolytic bacteria such as *Bifidobacterium*  
309 (*Bifidobacteriaceae*), *Fusicatenibacter* (*Lachnospiraceae*) and *Subdoligranulum*  
310 (*Ruminococcaceae*). Since adults, unlike children, may well exhibit a variety of comorbidities  
311 whose presence can have an additional obscuring influence on the microbiome (e.g.  
312 diabetes<sup>30</sup>, obesity<sup>31</sup>, and fatty liver disease<sup>32</sup>), it can be assumed that the data presented  
313 here are less influenced by such comorbidities and therefore appear to be more clearly CKD-  
314 associated.

315 The enrichment of *Enterobacteriaceae* found in HD patients affects the microbial metabolism  
316 of nutrients as they express tryptophanases that metabolize TRP to indoles<sup>29</sup>. Dietary TRP is  
317 metabolized both by somatic cells and by the intestinal microbiota to metabolites with various  
318 functions<sup>33,34</sup>. We found that TRP metabolites in the blood of CKD patients increased in a  
319 stage-dependent manner, which was predominantly driven by the disproportional increase of  
320 metabolites of bacterial origin. Therefore, dysbiosis and intestinal barrier dysfunction, as  
321 present in CKD and HD patients in our cohort, are likely contributing to the accumulation of  
322 uremic solutes<sup>35</sup> in addition to their reduced renal elimination<sup>29,36</sup>.

323 In our cohort, microbially-derived IxS and ILA as well as host-derived KYN, 3HK, KA, XA and  
324 AA were significantly elevated in CKD and HD patients, while serum levels of TRP were  
325 reduced. Both indole and KYN derivatives are ligands of the AhR, thereby influencing innate  
326 and adaptive immune responses<sup>10,33,34</sup>. Consequently, the AhR activation potential of serum

327 from our HD patients was increased, confirming previous findings in adults<sup>37</sup>. Of note, the  
328 degradation of TRP to KYN metabolites is regulated by tryptophan 2,3-dioxygenase in the  
329 liver, which is upregulated by chronic inflammation<sup>38</sup> and influenced by diabetes<sup>39-41</sup> and  
330 obesity<sup>42</sup>. In contrast to previous studies<sup>39-41</sup>, our study emphasizes enhanced TRP  
331 metabolism and AhR activation in CKD irrespective of traditional comorbidities.

332 Myeloid cells are known to be modulated by the AhR and are thus particularly affected by  
333 uremic TRP metabolites<sup>10,33,34</sup>. As indicated by unsupervised clustering and confirmed by  
334 hierarchical gating we demonstrated a pathological shift from classical towards intermediate  
335 and non-classical monocytes in HD patients. This monocyte signature has previously been  
336 associated with an increased risk of CVD<sup>43,44</sup>. Most notably, we showed that isolated  
337 monocytes exhibited a higher production of TNF- $\alpha$  after incubation with serum from patients  
338 treated by HD compared to HC, which was dependent on AhR function. Thus, the increased  
339 TNF- $\alpha$  concentrations in the circulation are at least partly a consequence of the effect of the  
340 increased and mainly microbially produced TRP metabolites on the AhR of monocytes, and  
341 possibly also other immune cells.

342 In line with the depletion of SCFA-generating saccharolytic bacteria<sup>45</sup>, such as  
343 *Bifidobacterium*, *Fusicatenibacter* and *Subdoligranulum* in CKD and HD patients, we show  
344 lower systemic levels of the SCFA propionate. There is a growing body of evidence about the  
345 pivotal role of SCFA in local gut homeostasis and the protection from CVD *in vitro*<sup>46</sup> and *in*  
346 *vivo*<sup>47</sup>. Since SCFA are known to enhance the abundance and suppressive function of Treg  
347 cells in mice<sup>48</sup> and humans<sup>49</sup>, we analyzed T cells by multi-color flow cytometry. Based on  
348 the expression of chemokine receptors<sup>14,50</sup>, we found a decrease of Th1-like, Th17-like and  
349 Th22-like Treg in HD patients. The lower frequencies of these Treg subtypes might be  
350 explained by both, lower peripheral induction as a consequence of reduced availability of  
351 SCFA<sup>48</sup> and increased recruitment of Treg to sites of inflammation, e.g. atherosclerotic  
352 plaques<sup>51</sup>. Moreover, the frequency of dysfunctional Treg with a central memory phenotype  
353 expressing PD-1 was elevated in HD patients. Circulating Treg expressing PD-1 are known



354 to exhibit reduced suppressive function and molecular signatures of exhaustion<sup>52</sup>. In light of  
355 the recognized importance of chronic inflammation for CVD development, the diminished  
356 anti-inflammatory function as a consequence of reduced abundances of Treg subtypes and  
357 increased abundances of dysfunctional, exhausted Treg is likely to play a role in CVD  
358 development<sup>50,51</sup>.

359 Interestingly, our unsupervised FlowSOM analysis clearly indicated that circulating MAIT  
360 cells were reduced in HD patients, expressed markers of exhaustion (PD-1) and produced  
361 higher amounts of IL-17A. This pattern has been described for several autoimmune,  
362 inflammatory and cardiometabolic diseases<sup>53</sup>, such as obesity and type two diabetes<sup>54</sup>. It is  
363 still a subject of discussion whether decreased MAIT cell abundances are mainly a  
364 consequence of migration to inflamed tissue or increased apoptosis<sup>53</sup>. In animal models,  
365 MAIT cells can promote inflammation and microbial dysbiosis leading to metabolic  
366 dysfunction during obesity<sup>53</sup>. A large cross-sectional analysis in patients with cardiometabolic  
367 diseases highlighted the positive association between decreased MAIT cell abundances and  
368 cardiovascular disease risk<sup>55</sup>. A reduction of MAIT cell abundance has been described in  
369 CKD of predominantly diabetic cause, albeit without functional cytokine expression as shown  
370 here<sup>56</sup>. Taken together, Treg and MAIT are two important cell populations phenotypically  
371 altered in HD patients that are known to be regulated by the microbiota, further emphasizing  
372 the importance of the microbiota-immune axis in CKD.

373 Noteworthy, patients after KT still showed significantly elevated serum levels of TNF- $\alpha$   
374 compared to HC, albeit lower than in CKD and HD. There were no differences in serum  
375 markers of intestinal barrier function and only slight alterations in the microbiota composition,  
376 although the limited size of our cohort is less suited to detect fine-scaled differences between  
377 HC and KT. While microbial SCFA and indole metabolism apparently recovers after KT,  
378 serum levels of KYN and 3HK were still elevated. In contrast, adult patients after KT  
379 exhibited a significant decrease in alpha diversity and an increase of Proteobacteria, which is  
380 in part driven by the use of immunosuppressive drugs<sup>57</sup>. In a murine kidney transplantation

381 model, mice after allograft transplantation exhibited dysbiosis even in the absence of  
382 antibiotics and immunosuppression<sup>58</sup>. As gut dysbiosis and impaired microbial production of  
383 SCFA seem to play a role in allograft rejection as well<sup>58</sup>, the absence of dysbiosis in children  
384 after KT might attribute to a more favorable transplant outcome in children compared to  
385 adults.

386 In conclusion, the present study is the first to show CKD stage-dependent alterations of the  
387 microbiota-metabolite-immune axis in children with CKD in the absence of comorbidities  
388 seen in adult patients. Our data demonstrate alterations at all levels of this pivotal axis. In  
389 this context, TRP metabolites act as a mechanistic link between the microbiota and the  
390 immune system, contributing to a pro-inflammatory phenotype in an AhR-dependent manner  
391 - even at a young age. SCFA deficiency may further exacerbate CKD-associated chronic  
392 inflammation and intestinal barrier dysfunction. These data provide strong evidence that the  
393 microbiota is an important stimulus for persistent inflammation. Restoring intestinal eubiosis  
394 could favorably influence the pro-inflammatory sequelae. Therefore, the microbiota appears  
395 a promising target of future therapeutic strategies aimed at sustained containment of  
396 inflammation to prevent chronic sequelae such as CVD and premature mortality in CKD.

## 397 **Acknowledgments**

398 This work was supported by local resources of the participating institutions. JH was  
399 supported by the Peter-Stiftung für die Nierenwissenschaft. JH, MW, SKF, and UL were  
400 supported by the German Center for Cardiovascular Research (DZHK), partner site Berlin.  
401 UL was supported by the German Federal Ministry of Education and Research (EMBARK;  
402 01K11909B) under the frame of JPI AMR (EMBARK; JPIAMR2019-109). S.G. was supported  
403 by the Bundesministerium für Bildung und Forschung funding MSTARs (Multimodal Clinical  
404 Mass Spectrometry to Target Treatment Resistance). F.B. was supported by the Berlin  
405 Institute of Health BIH-MD-TRENAL stipend. NW was supported by the European Research  
406 Council (ERC) under the European Union's Horizon 2020 research and innovation program  
407 (852796) and by a grant from the Corona-Stiftung in the German Stifterverband. NW and  
408 SKF were supported by the Deutsche Forschungsgemeinschaft (German Research  
409 Foundation, SFB 1365 and SFB 1470). The sponsors had no involvement in study design,  
410 data collection, analysis and interpretation of data and in the decision to submit this article for  
411 publication.

412 The authors thank Gudrun Koch, Jana Czychi, Gabriele N'diaye and Kerstin Sommer for  
413 their technical assistance and Nadine Unterwalder for her kind support in analyzing serum  
414 cytokine levels.

415

## 416 **Author contributions**

417 J.H., N.W. and D.M. led and conceived the project. J.H. and H.B. designed and performed  
418 most experiments, analyzed and interpreted the data. J.H., S.K., D.E. and L.D.K. conducted  
419 patient recruitment under supervision of D.M.. U.L., T.U.P.B., H.A. and S.K.F. performed the  
420 statistical analyses and data integration. J.H., H.B., M.I.W. and A.M. performed and analyzed  
421 flow cytometry. V.M.P. performed most of the *in vitro* experiments. A.T. and O.D. performed  
422 16S sequencing. D.L.V., M.K., S.G., S.K. and J.A.K. performed metabolite analysis. P.B.,

423 K.U.E., N.W., and D.M. helped with data interpretation. N.W. supervised the experiments and  
424 data analysis. J.H., H.B. and N.W. wrote the manuscript with key editing by F.B., U.Q. and  
425 K.U.E. and further input from all authors.

426


427 **Competing interest:** None declared.

428

429 **Data availability**

430 All data produced in the present study are available upon reasonable request to the authors.

431 **Figures**



432

433

**Figure 1: Arterial hypertension and systemic inflammation are linked to impaired**

434

**intestinal barrier function in pediatric chronic kidney disease.** The number of

435

antihypertensive drugs per individual (a, n= 48 patients) is shown in patients with chronic

436

kidney disease (CKD G3-4), hemodialysis (HD), after kidney transplantation (KT) and healthy

437

controls (HC). Plasma TNF- $\alpha$  (b, n=46 patients) was analyzed by chemiluminescence

438

immunoassay. Gut barrier function was assessed using Zonulin 1 and soluble CD14 (c, n=40

439

patients) ELISA measurements in plasma. Data is shown as a box (median and interquartile

440

range) and whiskers (min-max) with overlaid dot plot. *P* values  $\leq 0.05$  are shown, as


441

measured by ordinary one-way ANOVA or Kruskal-Wallis test followed by Tukey's or Dunn's

442


post-hoc correction for multiple comparisons, as appropriate.

443



444  
 445 **Figure 2: Characteristics of gut microbiota in a cohort of pediatric patients with**  
 446 **chronic kidney disease compared to healthy controls.** Analysis of gut microbiota from  
 447 16S rRNA sequencing in children (n = 32) with chronic kidney disease (CKD G3-4), patients  
 448 with hemodialysis (HD), patients after kidney transplantation (KT) and healthy controls (HC).  
 449 a) Relative abundance on phylum level of individuals according to their respective group. b)  
 450 Alpha diversity as measured by Shannon diversity. Data is shown as a box (median and  
 451 interquartile range) and whiskers (min-max) with overlaid dot plot. c) Beta diversity  
 452 assessment by Principal Coordinate Analysis (PCoA) based on Canberra distance (p = 0.01  
 453 by PERMANOVA). d) Analyses of group size differences on genus level are shown as a heatmap.  
 454 Patient groups were tested against each other (pairwise). The heatmap shows significant

455 changes in abundance using DESeq2 v1.30.1 package. Multiple groups of the same genus  
456 reported by Lotus due to lacking coverage in available phylogenetic databases are marked  
457 by numbers. Bar charts (right) show abundance and prevalence; abundance is calculated as  
458  $\log(\text{genus count})/\log(\max(\text{genus count}))$ ; prevalence for each genus is calculated across the  
459 whole data set. All significance estimates were adjusted for multiple tests using Benjamini-  
460 Hochberg FDR correction.




461

462 **Figure 3: Stage-dependent activation of plasma tryptophan metabolism activates the**  
 463 **Aryl-hydrocarbon receptor.** Tryptophan (TRP) and its metabolites were measured in  
 464 plasma of children at different stages of chronic kidney disease (CKD) compared to healthy  
 465 controls (n = 48). a) Multivariate analysis (Principal Coordinate Analysis) of all measured  
 466 metabolites discriminates between patients with CKD G3-4, patients with hemodialysis (HD),  
 467 patients after kidney transplantation (KT) and healthy controls (HC). b) Cumulative load of  
 468 TRP and its metabolites. c) Univariate analysis depicted as heatmap shows effect sizes  
 469 (Cliff's delta) for each pair of patient groups. Colours denote the effect directions (blue-  
 470 positive and red-negative) and magnitudes (the darker the colour, the stronger the  
 471 magnitude); asterisks represent the association significance. Statistical significance was  
 472 assessed by Mann-Whitney U-test and Benjamini-Hochberg false discovery rate correction.



473 Group differences of TRP (d), indoxyl sulfate (IxS, e) and kynurenin acid (KA, f) were further  
474 visualized in box plots. The Kynurenine/Tryptophan ratio (g) indicates the activity of  
475 tryptophan degradation to kynurenine metabolites. The activity of the Aryl-hydrocarbon  
476 receptor (AhR, h) was analyzed using a transfected reporter cell line after 48 hrs incubation  
477 with serum of HC (n=7) and HD (n=10) patients. *P* values  $\leq 0.05$  are shown, as measured by  
478 ordinary one-way ANOVA or Kruskal-Wallis test and adjusted by post-hoc Tukey's or Dunn's  
479 correction for multiple testing (d-g) or by t test (h). Data is shown as a box (median and  
480 interquartile range) and whiskers (min-max) with overlaid dot plot.


481 Abbreviations: TRP= tryptophan, 5OH-TRP= 5-hydroxy-tryptophan, TRYP= tryptamin, KYN=  
482 kynurenine, 3OH-KYN= 3-hydroxy-kynurenine, KA= kynurenic acid, AA= anthranilic acid,  
483 XA= xanthurenic acid, IxS= indoxyl sulfate; I3CA= indole-3-carboxyaldehyde, I3PA= indole-  
484 3-propionic acid, ILA= indole lactate, AhR= aryl hydrocarbon receptor.



485

486 **Figure 4: Correlation network of gut microbiome, clinical parameters, plasma**  
 487 **tryptophan metabolites and cytokines.** Laboratory parameters, tryptophan metabolites (n  
 488 = 48), cytokines (n=46) and taxonomic data (n = 32) were associated using pairwise  
 489 Spearman correlations and adjusted for multiple testing using the Benjamini-Hochberg FDR  
 490 correction. Edges for which absolute rho > 0.3 and Q < 0.1 are visualized. For better  
 491 visualization eGFR was removed as creatinine and urea convey similar information. a)  
 492 Positive correlations. b) Negative correlations.

493 Abbreviations: TRYP= tryptamin, TRP= tryptophan, KYN= kynurenine, KA= kynurenic acid,  
 494 3OH-KYN= 3-hydroxy-kynurenine, AA= anthranilic acid, XA= xanthurenic acid, PA= propionic  
 495 acid, BA= butyric acid, Iso-BA= isobutyric acid, Zo-1= zonulin-1, sCD14= soluble CD14, IxS=  
 496 indoxyl sulfate, ILA= indole lactate, I3CA= indole-3-carboxyaldehyde, I3PA= indole-3-  
 497 propionic acid, CrP= C-reactive protein. Crea= creatinine, phos= phosphate, Alb= albumin.




498

499 **Figure 5: Monocyte subtypes promote inflammation in chronic kidney disease.**

500 Monocytes isolated from healthy donors were incubated with serum from hemodialysis  
 501 patients (HD, n=7) and healthy controls (HC, n=7). Monocytes were incubated with indoxyl  
 502 sulfate (IxS) in presence or absence of the AhR antagonist CH-223191. TNF- $\alpha$  was  
 503 measured in the culture supernatant after 24 hrs incubation using ELISA (a). Peripheral  
 504 blood mononuclear cells (PBMC) were isolated from HD (n=6) and HC (n=7) individuals for  
 505 surface staining and multi-color flow cytometry was performed. Unsupervised clustering by  
 506 FlowSOM revealed 8 different cell clusters (b) characterized by the differential expression of  
 507 9 surface marker describing myeloid and dendritic cells (c). Cuneiform plots depict the log<sub>2</sub>-  
 508 fold changes for these clusters between HD and HC (indicated by color, size and  
 509 directionality of the triangles, d). Classical hierarchical gating of total monocytes, classical

510 monocytes (CD16+), non-classical (CD14+), and intermediate (CD14+CD16+) monocytes is  
511 shown in e).

512 Abbreviations: AhR= aryl hydrocarbon receptor.



513

514 **Figure 6: Pro-inflammatory T cell subtypes in chronic kidney disease.** Unsupervised  
 515 clustering of HD (n=6) and HC (n=7) individuals by FlowSOM revealed 8 T cell clusters (a)  
 516 based on the differential expression of surface marker (b). c) Cuneiform plots showing the  
 517 log2-fold changes for these clusters between HD and HC (indicated by color, size and  
 518 directionality of the triangles). Volcano plot of MAIT (d) and Treg (e) subpopulations by  
 519 hierarchical gating. y-axis indicates Q value by Mann-Whitney U-test and Benjamini-

520 Hochberg false discovery rate correction, x-axis log<sub>2</sub>-fold change between HD and HC.  
521 Significantly altered subpopulations are depicted as box (median and interquartile range) and  
522 whiskers (min-max) with overlaid dot plots for MAIT and Treg in f) and g), respectively. For f  
523 and g, *P* values ≤ 0.05 are shown, as measured by t test or Mann-Whitney-U test as  
524 appropriate.

525 Abbreviations: MAIT= mucosa-associated invariant T cells; Treg= regulatory T cells, HD=  
526 hemodialysis, HC= healthy controls.

527 **Tables**

528 **Table 1: Patients baseline characteristics.** Patients (n = 48) were grouped into four  
 529 categories (CKD = chronic kidney disease, HD = hemodialysis, KT = kidney transplantation,  
 530 HC = healthy controls). Data is shown as mean ± standard deviation or percentage (%) as  
 531 appropriate.

	<b>HC</b>	<b>CKD G3-G4</b>	<b>HD</b>	<b>KT</b>
<b>Patients (n)</b>	10	12	11	15
<b>Age (years)</b>	12.1 ± 4.2	8.3 ± 2.3	13.6 ± 3.2	9.1 ± 2.9
<b>Female</b>	7 (70%)	5 (42%)	3 (27%)	6 (40%)
<b>Diagnosis</b>				
<b>CAKUT</b>	N/A	5 (42%)	5 (45%)	8 (53%)
<b>Tubulointerstitial</b>	N/A	2 (17%)	1 (9%)	3 (20%)
<b>Glomerulopathy</b>	N/A	4 (33%)	4 (36%)	3 (20%)
<b>Post-AKI</b>	N/A	1 (8%)	1 (9%)	1 (7%)
<b>Healthy</b>	10 (100%)	N/A	N/A	N/A
<b>Caucasian</b>	9 (90%)	12 (100%)	3 (27%)	11 (73%)
<b>Weight (percentile)</b>	61 ± 23	38 ± 21	8 ± 7	52 ± 28
<b>BMI (percentile)</b>	57 ± 21	35 ± 19	31 ± 19	59 ± 25
<b>eGFR (ml/min/1.73 m<sup>2</sup>)</b>	100.2 ± 29.3	29.6 ± 14.6	6.6 ± 1.1	78.6 ± 19.4
<b>Urea (mg/dl)</b>	30 ± 7	112 ± 67	147 ± 39	36 ± 14
<b>Uric acid (mg/dl)</b>	4.8 ± 1.3	7.6 ± 2.2	6.7 ± 1.2	5.4 ± 1.4
<b>Phosphate (mmol/l)</b>	1.3 ± 0.1	1.6 ± 0.3	2.0 ± 0.5	1.5 ± 0.3
<b>Albumin (g/l)</b>	47.7 ± 5.3	43.8 ± 13.0	38.0 ± 4.8	40.0 ± 3.4
<b>CrP (mg/l)</b>	2.6 ± 5.9	0.7 ± 1.1	3.6 ± 6.9	2.0 ± 1.8
<b>PTH (pmol/l)</b>	N/A	13.2 ± 8.5	38.5 ± 38.4	7.7 ± 3.8
<b>Triglycerides (mg/dl)</b>	N/A	166 ± 75	186 ± 54	112 ± 57
<b>Antihypertensive treatment</b>	0 (0%)	10 (83%)	10 (91%)	8 (53%)
<b>Antihypertensive drugs (n)</b>	0	1.8 ± 1.5	2.4 ± 1.9	0.8 ± 0.9
<b>Arterial Hypertension (BP &gt; 95<sup>th</sup> Percentile)</b>	N/A	2 (17%)	6 (55%)	5 (33%)

532 Abbreviations: CAKUT = congenital anomalies of the kidney and urinary tract; Post-AKI =  
 533 patients with chronic kidney disease after acute kidney injury; BP = blood pressure; N/A = not  
 534 applicable.

## 535 References

- 536 1 Gansevoort, R. T. *et al.* Chronic kidney disease and cardiovascular risk: epidemiology,  
537 mechanisms, and prevention. *Lancet* **382**, 339-352, doi:10.1016/S0140-6736(13)60595-4  
538 (2013).
- 539 2 Claro, L. M. *et al.* The Impact of Uremic Toxicity Induced Inflammatory Response on the  
540 Cardiovascular Burden in Chronic Kidney Disease. *Toxins (Basel)* **10**,  
541 doi:10.3390/toxins10100384 (2018).
- 542 3 Onal, E. M., Afsar, B., Covic, A., Vaziri, N. D. & Kanbay, M. Gut microbiota and inflammation in  
543 chronic kidney disease and their roles in the development of cardiovascular disease.  
544 *Hypertens Res* **42**, 123-140, doi:10.1038/s41440-018-0144-z (2019).
- 545 4 Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of  
546 indoxyl sulfate and p-cresyl sulfate: a systematic review. *J Am Soc Nephrol* **25**, 1897-1907,  
547 doi:10.1681/ASN.2013101062 (2014).
- 548 5 Vaziri, N. D. *et al.* Chronic kidney disease alters intestinal microbial flora. *Kidney Int* **83**, 308-  
549 315, doi:10.1038/ki.2012.345 (2013).
- 550 6 Ramezani, A. *et al.* Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.  
551 *Am J Kidney Dis* **67**, 483-498, doi:10.1053/j.ajkd.2015.09.027 (2016).
- 552 7 Wang, X. *et al.* Aberrant gut microbiota alters host metabolome and impacts renal failure in  
553 humans and rodents. *Gut* **69**, 2131-2142, doi:10.1136/gutjnl-2019-319766 (2020).
- 554 8 Holle, J. *et al.* Indoxyl sulfate associates with cardiovascular phenotype in children with  
555 chronic kidney disease. *Pediatr Nephrol*, doi:10.1007/s00467-019-04331-6 (2019).
- 556 9 Harambat, J., van Stralen, K. J., Kim, J. J. & Tizard, E. J. Epidemiology of chronic kidney disease  
557 in children. *Pediatr Nephrol* **27**, 363-373, doi:10.1007/s00467-011-1939-1 (2012).
- 558 10 Rothhammer, V. & Quintana, F. J. The aryl hydrocarbon receptor: an environmental sensor  
559 integrating immune responses in health and disease. *Nat Rev Immunol* **19**, 184-197,  
560 doi:10.1038/s41577-019-0125-8 (2019).
- 561 11 Quintelier, K. *et al.* Analyzing high-dimensional cytometry data using FlowSOM. *Nat Protoc*  
562 **16**, 3775-3801, doi:10.1038/s41596-021-00550-0 (2021).
- 563 12 Abeles, R. D. *et al.* CD14, CD16 and HLA-DR reliably identifies human monocytes and their  
564 subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg)  
565 monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos)  
566 monocytes in acute liver failure. *Cytometry A* **81**, 823-834, doi:10.1002/cyto.a.22104 (2012).
- 567 13 Wong, K. L. *et al.* Gene expression profiling reveals the defining features of the classical,  
568 intermediate, and nonclassical human monocyte subsets. *Blood* **118**, e16-31,  
569 doi:10.1182/blood-2010-12-326355 (2011).
- 570 14 Duhon, T., Duhon, R., Lanzavecchia, A., Sallusto, F. & Campbell, D. J. Functionally distinct  
571 subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. *Blood* **119**,  
572 4430-4440, doi:10.1182/blood-2011-11-392324 (2012).
- 573 15 Jankowski, J., Floege, J., Fliser, D., Bohm, M. & Marx, N. Cardiovascular Disease in Chronic  
574 Kidney Disease: Pathophysiological Insights and Therapeutic Options. *Circulation* **143**, 1157-  
575 1172, doi:10.1161/CIRCULATIONAHA.120.050686 (2021).
- 576 16 Mitsnefes, M. M. Cardiovascular disease in children with chronic kidney disease. *J Am Soc*  
577 *Nephrol* **23**, 578-585, doi:10.1681/ASN.2011111115 (2012).
- 578 17 Schaefer, F. *et al.* Cardiovascular Phenotypes in Children with CKD: The 4C Study. *Clin J Am*  
579 *Soc Nephrol* **12**, 19-28, doi:10.2215/CJN.01090216 (2017).
- 580 18 Fasano, A. Zonulin and its regulation of intestinal barrier function: the biological door to  
581 inflammation, autoimmunity, and cancer. *Physiol Rev* **91**, 151-175,  
582 doi:10.1152/physrev.00003.2008 (2011).
- 583 19 Yuan, J. H. *et al.* Impaired intestinal barrier function in type 2 diabetic patients measured by  
584 serum LPS, Zonulin, and IFABP. *J Diabetes Complications* **35**, 107766,  
585 doi:10.1016/j.jdiacomp.2020.107766 (2021).



- 586 20 Tajik, N. *et al.* Targeting zonulin and intestinal epithelial barrier function to prevent onset of  
587 arthritis. *Nat Commun* **11**, 1995, doi:10.1038/s41467-020-15831-7 (2020).
- 588 21 Schutt, C., Schilling, T., Grunwald, U., Schonfeld, W. & Kruger, C. Endotoxin-neutralizing  
589 capacity of soluble CD14. *Res Immunol* **143**, 71-78, doi:10.1016/0923-2494(92)80082-v  
590 (1992).
- 591 22 Poesen, R. *et al.* Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular  
592 Disease, and Progression of Kidney Disease among Patients with CKD. *Clin J Am Soc Nephrol*  
593 **10**, 1525-1533, doi:10.2215/CJN.03100315 (2015).
- 594 23 Zaroni, I. & Granucci, F. Role of CD14 in host protection against infections and in metabolism  
595 regulation. *Front Cell Infect Microbiol* **3**, 32, doi:10.3389/fcimb.2013.00032 (2013).
- 596 24 Stanislawski, M. A. *et al.* Soluble CD14 Levels in the Jackson Heart Study: Associations With  
597 Cardiovascular Disease Risk and Genetic Variants. *Arterioscler Thromb Vasc Biol* **41**, e369-  
598 e378, doi:10.1161/ATVBAHA.121.316035 (2021).
- 599 25 Olson, N. C. *et al.* Soluble CD14, Ischemic Stroke, and Coronary Heart Disease Risk in a  
600 Prospective Study: The REGARDS Cohort. *J Am Heart Assoc* **9**, e014241,  
601 doi:10.1161/JAHA.119.014241 (2020).
- 602 26 Hiippala, K. *et al.* The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function  
603 and Alleviating Inflammation. *Nutrients* **10**, doi:10.3390/nu10080988 (2018).
- 604 27 Geirnaert, A. *et al.* Butyrate-producing bacteria supplemented in vitro to Crohn's disease  
605 patient microbiota increased butyrate production and enhanced intestinal epithelial barrier  
606 integrity. *Sci Rep* **7**, 11450, doi:10.1038/s41598-017-11734-8 (2017).
- 607 28 Hobby, G. P. *et al.* Chronic kidney disease and the gut microbiome. *Am J Physiol Renal Physiol*  
608 **316**, F1211-F1217, doi:10.1152/ajprenal.00298.2018 (2019).
- 609 29 Gryp, T. *et al.* Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria  
610 in Chronic Kidney Disease Patients. *Int J Mol Sci* **21**, doi:10.3390/ijms21061986 (2020).
- 611 30 Forslund, K. *et al.* Disentangling type 2 diabetes and metformin treatment signatures in the  
612 human gut microbiota. *Nature* **528**, 262-266, doi:10.1038/nature15766 (2015).
- 613 31 Bouter, K. E., van Raalte, D. H., Groen, A. K. & Nieuwdorp, M. Role of the Gut Microbiome in  
614 the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction. *Gastroenterology*  
615 **152**, 1671-1678, doi:10.1053/j.gastro.2016.12.048 (2017).
- 616 32 Chu, H., Williams, B. & Schnabl, B. Gut microbiota, fatty liver disease, and hepatocellular  
617 carcinoma. *Liver Res* **2**, 43-51, doi:10.1016/j.livres.2017.11.005 (2018).
- 618 33 Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease. *Nat*  
619 *Commun* **9**, 3294, doi:10.1038/s41467-018-05470-4 (2018).
- 620 34 Dodd, D. *et al.* A gut bacterial pathway metabolizes aromatic amino acids into nine  
621 circulating metabolites. *Nature* **551**, 648-652, doi:10.1038/nature24661 (2017).
- 622 35 Vaziri, N. D., Yuan, J. & Norris, K. Role of urea in intestinal barrier dysfunction and disruption  
623 of epithelial tight junction in chronic kidney disease. *Am J Nephrol* **37**, 1-6,  
624 doi:10.1159/000345969 (2013).
- 625 36 Poesen, R. *et al.* Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl  
626 sulfate in CKD. *Clin J Am Soc Nephrol* **8**, 1508-1514, doi:10.2215/CJN.00300113 (2013).
- 627 37 Dou, L. *et al.* Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney  
628 disease. *Kidney Int* **93**, 986-999, doi:10.1016/j.kint.2017.11.010 (2018).
- 629 38 Schefold, J. C. *et al.* Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum  
630 levels of tryptophan catabolites in patients with chronic kidney disease: a possible link  
631 between chronic inflammation and uraemic symptoms. *Nephrol Dial Transplant* **24**, 1901-  
632 1908, doi:10.1093/ndt/gfn739 (2009).
- 633 39 Mair, R. D., Sirich, T. L. & Meyer, T. W. Uremic Toxin Clearance and Cardiovascular Toxicities.  
634 *Toxins (Basel)* **10**, doi:10.3390/toxins10060226 (2018).
- 635 40 Debnath, S. *et al.* Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary  
636 to Type 2 Diabetes: Relationship to Inflammatory Markers. *Int J Tryptophan Res* **10**,  
637 1178646917694600, doi:10.1177/1178646917694600 (2017).

- 638 41 Pawlak, K., Kowalewska, A., Mysliwiec, M. & Pawlak, D. Kynurenine and its metabolites--  
639 kynurenic acid and anthranilic acid are associated with soluble endothelial adhesion  
640 molecules and oxidative status in patients with chronic kidney disease. *Am J Med Sci* **338**,  
641 293-300, doi:10.1097/MAJ.0b013e3181aa30e6 (2009).
- 642 42 Cussotto, S. *et al.* Tryptophan Metabolic Pathways Are Altered in Obesity and Are Associated  
643 With Systemic Inflammation. *Front Immunol* **11**, 557, doi:10.3389/fimmu.2020.00557 (2020).
- 644 43 Duni, A. *et al.* The Association of Circulating CD14<sup>++</sup>CD16<sup>+</sup> Monocytes, Natural Killer Cells  
645 and Regulatory T Cells Subpopulations With Phenotypes of Cardiovascular Disease in a  
646 Cohort of Peritoneal Dialysis Patients. *Front Med (Lausanne)* **8**, 724316,  
647 doi:10.3389/fmed.2021.724316 (2021).
- 648 44 Heine, G. H. *et al.* Monocyte subpopulations and cardiovascular risk in chronic kidney  
649 disease. *Nat Rev Nephrol* **8**, 362-369, doi:10.1038/nrneph.2012.41 (2012).
- 650 45 Felizardo, R. J. F., Watanabe, I. K. M., Dardi, P., Rossoni, L. V. & Camara, N. O. S. The interplay  
651 among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.  
652 *Pharmacol Res* **141**, 366-377, doi:10.1016/j.phrs.2019.01.019 (2019).
- 653 46 Bartolomaeus, H. *et al.* Short-Chain Fatty Acid Propionate Protects From Hypertensive  
654 Cardiovascular Damage. *Circulation* **139**, 1407-1421,  
655 doi:10.1161/CIRCULATIONAHA.118.036652 (2019).
- 656 47 Hsu, C. N., Lu, P. C., Hou, C. Y. & Tain, Y. L. Blood Pressure Abnormalities Associated with Gut  
657 Microbiota-Derived Short Chain Fatty Acids in Children with Congenital Anomalies of the  
658 Kidney and Urinary Tract. *J Clin Med* **8**, doi:10.3390/jcm8081090 (2019).
- 659 48 Arpaia, N. *et al.* Metabolites produced by commensal bacteria promote peripheral regulatory  
660 T-cell generation. *Nature* **504**, 451-455, doi:10.1038/nature12726 (2013).
- 661 49 Haghikia, A. *et al.* Propionate attenuates atherosclerosis by immune-dependent regulation of  
662 intestinal cholesterol metabolism. *Eur Heart J*, doi:10.1093/eurheartj/ehab644 (2021).
- 663 50 Halim, L. *et al.* An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like  
664 Tregs that Support a Tumorigenic Environment. *Cell Rep* **20**, 757-770,  
665 doi:10.1016/j.celrep.2017.06.079 (2017).
- 666 51 Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. *Nat Rev*  
667 *Cardiol* **17**, 387-401, doi:10.1038/s41569-020-0352-5 (2020).
- 668 52 Lowther, D. E. *et al.* PD-1 marks dysfunctional regulatory T cells in malignant gliomas. *JCI*  
669 *Insight* **1**, doi:10.1172/jci.insight.85935 (2016).
- 670 53 Toubal, A. *et al.* Mucosal-associated invariant T cells promote inflammation and intestinal  
671 dysbiosis leading to metabolic dysfunction during obesity. *Nat Commun* **11**, 3755,  
672 doi:10.1038/s41467-020-17307-0 (2020).
- 673 54 Magalhaes, I. *et al.* Mucosal-associated invariant T cell alterations in obese and type 2  
674 diabetic patients. *J Clin Invest* **125**, 1752-1762, doi:10.1172/JCI78941 (2015).
- 675 55 Touch, S. *et al.* Mucosal-associated invariant T (MAIT) cells are depleted and prone to  
676 apoptosis in cardiometabolic disorders. *FASEB J*, fj201800052RR,  
677 doi:10.1096/fj.201800052RR (2018).
- 678 56 Juno, J. A. *et al.* Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered  
679 Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating  
680 Factor Production During End-Stage Renal Disease. *Front Immunol* **9**, 1076,  
681 doi:10.3389/fimmu.2018.01076 (2018).
- 682 57 Swarte, J. C. *et al.* Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant  
683 Recipients. *J Clin Med* **9**, doi:10.3390/jcm9020386 (2020).
- 684 58 Wu, H. *et al.* Gut Microbial Metabolites Induce Donor-Specific Tolerance of Kidney Allografts  
685 through Induction of T Regulatory Cells by Short-Chain Fatty Acids. *J Am Soc Nephrol*,  
686 doi:10.1681/ASN.2019080852 (2020).

687